Abstract
We previously described a strategy for selecting highly adaptable rare triple-negative breast cancer (TNBC) cells based on their ability to survive a severe and prolonged metabolic challenge, e.g., a lack of glutamine. We hypothesized that metabolically adaptable (MA) cancer cells selected from the SUM149 cell line in this manner have the capacity to survive a variety of challenges that postulated “decathlon winner” cancer cells must survive to succeed in metastasis. These MA cells were resistant to glutaminase inhibitor CB-839, as predicted from their ability to proliferate without exogenous glutamine. They were also resistant to hypoxia, surviving treatment with hypoxia inducer cobalt chloride. Investigating the nature of intrinsic resistance in SUM149-MA cells, we found that 1–2 mM metformin completely inhibited the emergence of MA colonies in SUM149 cells in glutamine-free medium. These highly resistant MA cells grew into colonies upon removal of metformin, indicating that they survived in quiescence for several weeks under metformin treatment. This approach of selecting resistant cells worked equally well with additional TNBC cell lines, specifically inflammatory breast cancer cell line FC-IBC02 and mouse breast cancer cell line 4T07. In both cases, less than 1% of cells survived metformin treatment and formed colonies in glutamine-free medium. The MA cells selected in this manner were significantly more resistant to the chemotherapeutic drug doxorubicin than the parental cell lines. We conclude that our approach may be useful in developing usable models of cancer cell quiescence and therapy resistance in TNBC.
Highlights
Cancer is an evolution-like process involving various mechanisms for generating tumor cell diversity and the selective pressures that operate in the body [1,2,3,4]
We hypothesized that metabolically adaptable (MA) cancer cells selected from the SUM149 cell line in this manner have the capacity to survive a variety of challenges that postulated “decathlon winner” cancer cells must survive to succeed in metastasis
To determine whether SUM149MA cells are more resistant to hypoxia than the parental SUM149 cell line, we employed cobalt chloride to generate “chemical hypoxia” in cells
Summary
Cancer is an evolution-like process involving various mechanisms for generating tumor cell diversity and the selective pressures that operate in the body [1,2,3,4]. We must get better at developing therapies that inhibit cancer evolution To meet this challenge, we are pursuing a novel approach for modeling the cancer cells that drive cancer evolution. If a highly abnormal cancer cell can survive a prolonged severe metabolic challenge, this cell can survive most hurdles, including standard therapies and immune therapies. Given these premises, we are developing an in vitro model of the most evolvable and resistant “decathlon winner” cancer cells [3] that can be used to discover effective new therapies for cancers that do not respond to currently offered therapies
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
